GCM
SRNE

Graham Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Graham Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,947
Closed -$12.4K – 1404
2022
Q4 		$12.4K Sell
13,947
-830,998
-98% -$1.1M ﹤0.01% 1011
2022
Q3 		$1.33M Buy
+844,945
New +$1.92M 0.05% 363

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Graham Capital Management's SRNE Position: Q1 2023 in Review

Graham Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 13,947 shares — an estimated $12.4K sold.

Graham Capital Management first reported a position in SRNE in Q3 2022 and held it in 2 quarters. The position peaked at $1.33M in Q3 2022. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Graham Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Graham Capital Management sold 13,947 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $12.4K.
  • Graham Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2022 and held it in 2 quarters.
  • Graham Capital Management's Sorrento Therapeutics, Inc. position peaked at $1.33M in Q3 2022.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Graham Capital Management's 13F filing for Q1 2023, filed 15 May 2023.